Document title	**DECLARATION OF NON-INITIATION OF THE CLINICAL TRIAL**
Study title	**A 2-Part, Open-label, Non-randomized (Part A) and Randomized, Double-blinded, Placebo-controlled (Part B) multicentric, international study with adaptive design to evaluate safety and tolerability of bazedoxifene, concentrated solution for nebulization (BAZE-X1) in addition to Standard of Care in hospitalized COVID-19 patients suffering from moderate to severe Pneumonia**
Test drug code	**BAZE-X1**
Indication	**COVID-19 pneumonia**
Development phase	**Phase II**
Protocol number	**OB003**
EudraCT number	**2021-005247-78**
Sponsor	**Oxygen Biotech s.r.o.** **Italská 2581/67** **120 00 Prague 2 – Vinohrady** **Czech Republic**
Planned participating countries	**Czech Republic, Slovakia**
Study global initiation date (FVFP)	**N.A.**
Study global completion date (LVLP)	**N.A.**
Date of the declaration	**05 December 2024**

The sponsor of this clinical trial confirms that no participants were enrolled in any country, and no informed consent form was signed. As a result, the clinical trial was not initiated. Following a comprehensive strategic review of the development of the investigational medicinal product (IMP), the sponsor decided not to proceed with the clinical trial. Consequently, the trial has been classified as prematurely interrupted, and no results are available.